Emergent BioSolutions
Presence
Emergent BioSolutions is one of the...
Emergent BioSolutions is a company listed under the stock ticker EBS (US).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Emergent BioSolutions
- Robert Kramer, Director, President and Chief Executive Officer
- Zsolt Harsanyi, Chairman of the Board
- Jerome Hauer, Director
Popular executive movements at Emergent BioSolutions
- Brian Millard who is Senior Vice President and Corporate Controller, will be promoted to Chief Financial Officer on Sep. 6, 2022 (posted on August 5 2022).
- Richard Lindahl, Executive Vice President, Chief Financial Officer and Treasurer, will retire on Sep. 6, 2022 (posted on August 5 2022).
- Sujata Dayal has joined the company as Director (posted on July 7 2022).
Click here to view some more movements at Emergent BioSolutions
Create an alert
to follow the executive moves at Emergent BioSolutions.
Pharmaceuticals
Emergent BioSolutions has 1,995 competitors including Johnson & Johnson (United States (USA)), Pfizer (United States (USA)) and Roche (Switzerland).
Popular M&A news in Pharmaceuticals
- CSL has acquired Vifor Pharma (posted on August 4 2022).
- PharmEasy has just announced a $200 Million fundraising. (posted on July 19 2022).
- Syros Pharmaceuticals has just announced a $190 Million fundraising. (posted on July 5 2022).
Popular contacts in Pharmaceuticals
News
Press releases by Emergent BioSolutions
- Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019 | Emergent BioSolutions Inc.
- Emergent BioSolutions to Host 2019 Analyst & Investor Day | Emergent BioSolutions Inc.
- Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense | Emergent BioSolutions Inc.
- Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder | Emergent BioSolutions Inc.
- Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate | Emergent BioSolutions Inc.
- Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference | Emergent BioSolutions Inc.
- Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019 | Emergent BioSolutions Inc.
- Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology | Emergent BioSolutions Inc.
- Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense | Emergent BioSolutions Inc.
- Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance | Emergent BioSolutions Inc.
- View more press releases Close
Social media about Emergent BioSolutions
- Emergent BioSolutions on Wikipedia, Google News & Yahoo Finance
- Emergent BioSolutions on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Robert Kramer 
Call Emergent BioSolutions at +1 301...
